# Clive Meanwell

> Clive Meanwell is a Series A investor at Population Health Partners backing Biotechnology. See 4 investments, round sizes, portfolio and contact details…

- Type: Angel Investor
- Fund: [Population Health Partners](https://shizune.co/investors/profile/population-health-partners)
- Location: New York, United States
- Total investments: 4
- Last investment: Jan 2026
- Lead investor: 50%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/pub/clive-meanwell/10/412/201

Clive Meanwell is a Series A investor at Population Health Partners in New York focused on Biotechnology and Health Care. Clive A. Meanwell has been a director since 1996. He has served as our chief executive officer since February 2012, our chief executive officer and president from October 2009 to February 2012, as our chief executive officer from August 2004 to October 2009, as our president from August 2004 to December 2004, our executive chairman from September2001 to August 2004 and as our chief executive officer and president from 1996 to September 2001. From 1995 to 1996, Dr. Meanwell was a partner and managing director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including senior vice president from 1992 to 1995, vice president from 1991 to 1992 and director of product development from 1986 to 1991. Dr. Meanwell received an M.D. and a Ph.D. from the University of Birmingham, United Kingdom.

## Contacts

5 contacts available for Clive Meanwell: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/clive-meanwell?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Health Care | 2 | 50% |
| Therapeutics | 2 | 50% |
| Medical | 1 | 25% |
| Life Science | 1 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Series F | 1 | 25% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Corsera Health | Corsera Health develops preventive RNA interference medicines focused on reducing cardiovascular disease risk before long-term damage occurs. The company’s approach targets two biological drivers of cardiovascular disease by silencing PCSK9 to lower LDL cholesterol and AGT to reduce blood pressure. Its RNAi platform works by decreasing theproduction of these proteins at the gene expression level, aiming to alter disease progression through early intervention. Corsera Health designs its medicines for once-yearly administration to support long-term adherence and simplify preventive care. The company’s development strategy emphasizes broad population use and accessibility through scalable manufacturing and pricing structures suited for preventive treatment. | $80M | Series A | Jan 07, 2026 | https://corserahealth.com |
| Areteia Therapeutics | Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments. | $75M | Series A | Feb 13, 2024 | https://areteiatx.com/ |
| Areteia Therapeutics | Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication ofimproving lung function and is found in several asthma-related treatments. | $350M | Series A | Jul 12, 2022 | https://areteiatx.com/ |
| Fractyl Health | Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease. | $100M | Series F | Jun 16, 2021 | http://www.fractyl.com |

4 of 4 investments shown.

## Co-investors
- [Maverick Capital](https://shizune.co/investors/profile/maverick-capital-6d16) — VC Fund, 3 deals together
- [Access Biotechnology](https://shizune.co/investors/profile/access-biotechnology) — VC Fund, 2 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 2 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 2 deals together
- [Sanofi](https://shizune.co/investors/profile/sanofi) — VC Fund, 2 deals together

## About Population Health Partners

VC Fund · San Francisco, United States

Population Health Partners is an investment company focused on innovative therapeutics with the potential to transform health outcomes for populations.

5 contacts available at Population Health Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Farah Champsi | Partner | https://shizune.co/investors/profile/farah-champsi |
| Clive Meanwell | Executive Chairman & Co-Founder | https://shizune.co/investors/profile/clive-meanwell |
| Greg Williams | Venture Partner | https://shizune.co/investors/profile/greg-williams-ebcd |
| Tom Denwood | Chief Digital Officer | https://shizune.co/investors/profile/tom-denwood |
| Whit Bernard | Managing Partner | https://shizune.co/investors/profile/whit-bernard-bed1 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Clive Meanwell invest in?

Clive Meanwell invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series F stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Clive Meanwell?

Public channels for Clive Meanwell include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Clive Meanwell last invest?

The most recent investment recorded for Clive Meanwell closed in Jan 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co